Stryker to Report Third-Quarter Results on October 29 After Previous-Quarter Sales of $6.6 Billion
Key Facts
Stryker is scheduled to report third-quarter 2026 results on October 29, with a release expected at about 4:05 p.m. Eastern time, ahead of a results call at 4:30 p.m., according to the company’s investor relations page. The announcement follows a second quarter in which the company recorded growth in reported and organic sales, while investors are focused on demand indicators and the company’s ability to manage manufacturing constraints. Estimates ahead of the announcement pointed to adjusted earnings of $3.55 per share and revenue of $6.62 billion, according to a Reuters report published via Investing.com. These are estimates, not actual results, and the available evidence here does not include the company’s third-quarter results.
In the second quarter, reported sales rose 9.4% to $6.6 billion, while organic sales increased 9.0%, according to the filing submitted to the U.S. Securities and Exchange Commission. The two figures show sales performance ahead of the new announcement, distinguishing reported growth from organic growth, which the company uses to present operating performance. Adjusted earnings per share reached $3.69, up 17.9% from the same period. These results provide a recent basis for comparison when assessing the company’s annual performance update, but on their own they do not determine the direction of third-quarter results.
The company’s latest available official guidance, issued on July 30, projected organic sales growth of 8.3% to 9.3% in fiscal 2026. Stryker also set an adjusted earnings outlook of $14.95 to $15.10 per share. The guidance was included in the second-quarter filing and is the available official reference for assessing any subsequent revision. The guidance attributed to the company in the previous version of the story is not supported by the information available here. Any change to the full-year range therefore remains subject to what the company announces in its third-quarter release or on its call.
A Reuters report ahead of the results highlighted manufacturing constraints in the peripheral vascular business, saying their effects could persist through the fourth quarter. It also pointed to a weak recovery in joint replacement procedures, particularly hips. By contrast, the report said demand for capital hospital equipment was strong, creating a backlog of orders, and that Trauma & Extremities remained a source of strength. These factors leave the company facing a mix of supply pressures and sources of demand support as investors await management’s details on the business outlook. The report cited estimates ahead of the announcement of $3.55 per share and $6.62 billion in revenue, without presenting them as actual results.
In a separate strategic move in October, Stryker announced an approximately $400 million preferred investment in CMR Surgical, along with an exclusive option to acquire it and take on exclusive U.S. distribution of the Versius robot. The agreement adds a robotics surgery dimension to investors’ monitoring of the company’s existing businesses. In the market, SYK shares closed at $304 on October 28, according to EL7 data. The release is expected on October 29 at about 4:05 p.m. Eastern time, followed by the company’s call at 4:30 p.m.